Immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
1. A composition comprising
(a) at least one isolated Neisseria meningitidis serogroup B ORF2086 protein belonging to subfamily A having the amino acid sequence of SEQ ID NO: 301, wherein x is any amino acid; wherein the region from amino acid position 5 to amino acid position 8 is any of 0 to 4 amino acids; wherein the region from amino acid position 66 to amino acid position 68 is any of 0 to 3 amino acids; wherein the ORF2086 protein belonging to the subfamily A comprises the amino acid sequence of SEQ ID NO: 278; and
(b) at least one isolated Neisseria meningitidis serogroup B ORF2086 protein belonging to subfamily B having the amino acid sequence of SEQ ID NO: 302, wherein x is any amino acid; and wherein the region from amino acid position 8 to amino acid position 12 is any of 0 to 5 amino acids; and wherein the ORF2086 protein belonging to the subfamily B comprises the amino acid sequence of SEQ ID NO: 279; wherein the composition further comprises an immunostimulatory amount of aluminum hydroxide or aluminum phosphate.
2. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein has a molecular weight of 26-30 kDa as measured by mass spectroscopy.
3. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein has a molecular weight of 28-35 kDa as measured on a 10%-20% SDS polyacrylamide gel.
4. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein is non-lipidated.
5. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein is lipidated.
6. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein is a recombinant protein.
7. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein is a fusion protein.
8. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein is conjugated to a carrier.
9. The composition of claim 1 , wherein said composition additionally comprises a pharmaceutically acceptable buffer, diluent, adjuvant or carrier.
10. The composition of claim 1 , further comprising at least one PorA, PorB, transferrin binding protein, opacity protein (Opc) or an additional surface antigen of Neisseria species, said additional surface antigen being a non-ORF2086 protein.
11. The composition of claim 1 , wherein said composition additionally comprises a polysaccharide.
12. The composition of claim 11 , wherein the polysaccharide is a meningococcus serogroup A, C, Y or W 135 polysaccharide or a conjugate thereof.
13. The composition of claim 1 , wherein the at least one Neisseria meningitidis serogroup B ORF2086 protein elicits bactericidal antibodies to multiple strains of N. meningitidis.
14. A method of inducing an immune response in a mammal comprising administering to the mammal an immunogenically effective amount of the composition of claim 1 .